Elagolix: A Comprehensive Guide for API Importers, Manufacturers, and Compounding Pharmacies
The pharmaceutical landscape is constantly evolving, driven by innovative active pharmaceutical ingredients (APIs) that address complex medical conditions.
For API importers, drug manufacturers, and compounding pharmacies, staying ahead of the curve on these novel compounds is not just an advantage—it’s a necessity for business growth and sustainability.
Elagolix Sodium has emerged as one of the most significant endocrine APIs in recent years, representing a paradigm shift in the treatment of estrogen-dependent conditions.
This comprehensive guide is your definitive resource on Elagolix Sodium API.
We move beyond basic pharmacology to deliver the critical, in-depth intelligence you need to make informed decisions.
Whether you’re evaluating your supply chain, developing a new formulation, or planning a compounding strategy, this post provides the technical data, market analysis, and strategic insights to position your operations for success in the burgeoning Elagolix market.
What is Elagolix?
Elagolix sodium is a first-in-class, orally administered, non-peptide, potent antagonist of the gonadotropin-releasing hormone (GnRH) receptor.
It is chemically known as N-[(4R)-4-ethyl-1,1-dioxido-8-(naphthalen-2-ylmethyl)-3,4-dihydro-2H-thieno[3,2-e][1,2]thiazin-7-yl]methanesulfonamide sidum.
As a GnRH receptor antagonist, Elagolix works by directly blocking the pituitary GnRH receptors.
This action suppresses the release of gonadotropins—luteinizing hormone (LH) and follicle-stimulating hormone (FSH)—which in turn leads to a dose-dependent reduction in the production of ovarian sex hormones, primarily estrogen and progesterone.
For industry professionals, its key differentiators are:
Oral Bioavailability: Unlike older peptide GnRH agonists (e.g., Leuprolide), which require injection, Elagolix’s small-molecule structure enables oral administration, thereby vastly improving patient compliance and enabling simpler formulation options.
Rapid Onset of Action: It does not cause the initial “flare-up” effect associated with GnRH agonists, providing a more predictable and immediate therapeutic response.
Reversible Effect: Upon discontinuation, hypothalamic-pituitary-ovarian (HPO) axis function typically returns to baseline relatively quickly, which is a crucial consideration for family planning.
Understanding these core characteristics is the first step in appreciating its market potential and technical handling requirements.
What are the Brand Names of Elagolix?
The primary brand name for Elagolix is Orilissa®.
It is marketed by AbbVie Inc., which developed the drug following its acquisition of Neurocrine Biosciences’ collaboration partner.
Orilissa® is available in two strengths: 150 mg and 200 mg film-coated tablets.
API buyers and compounders should note that, while Orilissa is the branded product, the API is universally referred to as Elagolix or Elagolix Sodium.
As the patent exclusivity period progresses, the market for the generic API is expected to expand significantly.
Keeping abreast of patent expiration dates in key markets (e.g., the US, EU) is essential for forecasting supply, demand, and pricing volatility.
When sourcing the API, you may also encounter it under its CAS Registry Number: 832720-36-2. Using this unique identifier is a best practice to ensure precision in chemical procurement and avoid confusion with similarly named compounds.
What is Elagolix Used For?
Elagolix is approved for the management of moderate to severe pain associated with endometriosis.
It represents a significant therapeutic advancement for the millions of women worldwide affected by this chronic and often debilitating condition.
Endometriosis is an estrogen-dependent disorder characterized by the growth of endometrial-like tissue outside the uterus.
This tissue responds to hormonal cycles, leading to inflammation, pain, and the formation of adhesions.
By suppressing estrogen production, Elagolix creates a hypoestrogenic environment that helps to reduce the inflammation and growth of these ectopic lesions, thereby alleviating the associated pain.
The FDA-approved indications are specifically:
Management of moderate to severe pain associated with endometriosis.
For Compounding Pharmacies: Understanding the off-label demand is key.
There is growing interest and evidence for the use of Elagolix in other estrogen-mediated conditions, which presents a significant opportunity for specialized compounding services.
These include:
Uterine Fibroids (Leiomyomas): To manage heavy menstrual bleeding.
Adenomyosis: A condition where endometrial tissue grows into the uterine muscle wall.
Assisted Reproductive Technologies (ART): As part of controlled ovarian stimulation protocols.
Staying informed about ongoing clinical trials for these and other potential applications can provide a first-mover advantage in the compounding space.
How Does Elagolix Work? (Mechanism of Action)
A deep understanding of the Mechanism of Action (MoA) is vital for manufacturers and compounders to appreciate stability concerns, potential interactions, and the rationale for use.
GnRH Receptor Blockade: In a healthy menstrual cycle, GnRH is released from the hypothalamus in a pulsatile manner, binding to receptors on pituitary gonadotrophs to stimulate the synthesis and release of FSH and LH.
Suppression of Gonadotropins: Elagolix competitively binds to the GnRH receptors in the pituitary gland. This blockade inhibits post-receptor signaling, resulting in immediate suppression of FSH and LH secretion. There is no initial surge in gonadotropins (the “flare-effect” seen with agonists).
Ovarian Suppression: With reduced levels of FSH and LH, the ovarian follicles are not adequately stimulated. This results in profound suppression of ovarian estradiol (the primary estrogen) and progesterone production.
Dose-Dependent Effect: The level of estrogen suppression is dose-dependent.
The 150 mg once-daily dose provides partial suppression.
The 200 mg twice-daily dose provides near-complete suppression.
This MoA is the cornerstone of its efficacy in treating endometriosis, a condition that thrives in an estrogen-rich environment.
Elagolix Dosage and Administration
For those involved in manufacturing tablets or compounding alternative dosage forms, precise knowledge of the approved dosing regimens is non-negotiable.
Recommended Dosage: Individualized based on symptom severity and the intended duration of treatment.
150 mg dose: Taken orally, once daily. Recommended for use for up to 24 months.
200 mg dose: Taken orally, twice daily. Recommended for use for up to 6 months due to a greater risk of bone density loss.
Administration: Can be taken with or without food. This flexibility is a positive point for patient adherence.
Critical Considerations for Industry:
Dose Proportionality: Exposure (Cmax and AUC) increases proportionally with dose, which is essential for formulating different strengths of the medication.
Half-life: Elagolix has a relatively short half-life (~4-6 hours), necessitating once or twice-daily dosing. It is a key factor for formulation scientists considering extended-release mechanisms.
Starting Material: Dosing is based on the elagolix free acid equivalent.
Elagolix Precautions and Drug Interactions
Precautions:
Bone Loss: Elagolix causes a dose-dependent decrease in bone mineral density (BMD). The recommended duration of use is limited for this reason. Manufacturers/compounders should be aware that future formulations may include combinatory products with add-back therapy (e.g., low-dose norethindrone acetate).
Hepatic Impairment: Dose adjustment is required for patients with moderate hepatic impairment. It is not recommended for severe impairment. It impacts labeling and safety data required for regulatory filings.
Suicidal Ideation and Mood Disorders: Warnings exist about the potential for mood changes and depression. It is a class effect of hormonal suppression.
Drug Interactions:
Elagolix is a substrate of CYP3A and P-glycoprotein (P-gp). More importantly, it is a moderate inducer of CYP3A and a weak inhibitor of CYP2C9. This profile is crucial for anticipating interactions in patients with polypharmacy and for compounding combination products.
Strong and Moderate CYP3A Inducers (e.g., Rifampin, Carbamazepine, St. John’s Wort):
Effect: May decrease Elagolix plasma concentrations.
Recommendation: Concomitant use is not recommended. This is crucial information for pharmacists counseling patients.
Strong CYP3A Inhibitors (e.g., Ketoconazole, Itraconazole):
Effect: May increase Elagolix plasma concentrations.
Recommendation: Concomitant use is not recommended with the 200 mg twice-daily dose. Use with caution with the 150 mg dose.
OATP1B1 Substrates (e.g., Statins like Atorvastatin, Rosuvastatin):
Effect: Elagolix may increase its concentrations.
Recommendation: Monitor for adverse reactions to these drugs.
A comprehensive drug interaction study is a must for any company developing a new product containing Elagolix.
What are the Side Effects of Elagolix?
Understanding the adverse event profile is essential for risk management, patient counseling materials, and positioning your product.
The most common adverse reactions (≥5%) are a direct consequence of its estrogen-lowering effect:
Hot flushes (flashes) and night sweats
Headache
Nausea
Insomnia
Amenorrhea (absence of menstruation) and irregular uterine bleeding
Mood changes, including anxiety and depression
Arthralgia (joint pain)
Fatigue
The frequency and severity of these events are generally dose-dependent.
For Compounding Pharmacies: You may consider combining supportive therapies to manage these side effects (e.g., complementary natural products for mood support, under a doctor’s direction), making the overall treatment regimen more tolerable and improving patient retention.
Elagolix vs. Other Medications
Positioning Elagolix in the treatment landscape is key for marketing and educational efforts.
| Medication (Class) | Route | Key Differentiator | Advantage | Disadvantage |
|---|---|---|---|---|
| Elagolix (GnRH Antagonist) | Oral | Immediate suppression, no flare-up; Oral administration | High patient compliance; rapid onset | Higher cost; bone density loss |
| Leuprolide (GnRH Agonist) | Injection | Causes an initial hormonal flare | Long history of use; long-acting forms | Flare-effect; injection-only; more profound hypoestrogenism |
| NSAIDs (e.g., Ibuprofen) | Oral | Pain relief only | Inexpensive; easily accessible | Does not treat underlying disease; GI side effects |
| Oral Contraceptives (Levonorgestrel) | Oral | Suppresses ovulation | Also provides contraception | May be less effective for severe pain |
| Danazol (Androgen) | Oral | Creates a high-androgen state | Effective for pain | Androgenic side effects (acne, hirsutism) are often poorly tolerated |
Unique Selling Proposition for Elagolix: It offers a balance of efficacy and tolerability with the unparalleled convenience of oral dosing.
Is Elagolix safe during pregnancy?
No. Elagolix is contraindicated in pregnancy.
It is classified as FDA Pregnancy Category X: Studies in animals or humans have demonstrated fetal abnormalities, and the risk of use in pregnant women clearly outweighs any potential benefit.
Mechanism: By suppressing estrogen and progesterone, Elagolix creates a hormonal environment that is incompatible with maintaining a pregnancy.
Requirements: Pregnancy must be excluded before starting therapy. Patients of reproductive potential must use effective non-hormonal contraception (e.g., copper IUD, barrier methods) during and for one week after treatment, as Elagolix can render hormonal contraceptives less effective.
This is a critical safety point that must be prominently featured in all informational and labeling materials.
How long does Elagolix take to work?
Patients typically experience a reduction in endometriosis pain within the first 1-2 months of therapy.
The rapid onset is due to its direct antagonistic action. Clinical trials showed a statistically significant reduction in dysmenorrhea (menstrual pain) and non-menstrual pelvic pain compared to placebo as early as the first month.
For Marketing: This “rapid response” is a powerful messaging tool compared to treatments that may take longer to show effect.
Global Sourcing Tips of Elagolix API
Verify Regulatory Status: Before sourcing, confirm the regulatory status in your target market to ensure compliance. Is the API approved? Is a Drug Master File (DMF) available and active with the relevant health authority (e.g., US FDA, EMA, PMDA)?
Supplier Qualification is Paramount: Do not prioritize cost over quality—partner with suppliers who have a proven track record of excellence. of success
Audit: Conduct rigorous audits (on-site or virtual) of the manufacturer’s facilities. Verify their GMP compliance (ICH Q7 guidelines).
Quality Documentation: Request and review the Certificate of Analysis (CoA), Stability Data, and the Manufacturer’s Working Cell Bank (MCB) information for the synthesis process.
Understand the Synthesis Pathway: Elagolix synthesis is a complex process, involving multiple steps. A supplier’s expertise and control over their starting materials and intermediates directly impact the quality, purity, and consistency of the final API.
Purity and Impurity Profile: Scrutinize the CoA for:
Assay: Should be ≥ 98.0% – 102.0%.
Related Substances: Closely monitor specified and unspecified impurities. Ensure they are within ICH Q3A guidelines.
Residual Solvents: Must comply with ICH Q3C.
Particle Size Distribution: Critical for formulation bioavailability and blend uniformity.
Supply Chain Transparency: Ensure your supplier provides full traceability of materials. Be wary of brokers who cannot identify the original manufacturer transparently.
Logistics and Storage: Elagolix API typically requires storage at 2-8°C. Ensure your logistics partner maintains an unbroken cold chain and provides temperature-monitoring data throughout the shipment.
Compounding Pharmacy Guidelines for Elagolix Formulations
Compounding pharmacies can fill a vital niche, especially for patients who cannot tolerate commercial tablets or need customized dosing.
Source API, Not Crushed Tablets: Always use pharmaceutical-grade Elagolix API from a qualified supplier. Crushing commercial tablets (Orilissa) introduces excipients that can interfere with stability, bioavailability, and dosing accuracy.
Excipient Compatibility: Conduct thorough research on compatibility. Standard compounding vehicles, such as suspending agents (e.g., SyrSpend SF) and preservatives, must not degrade the API. Perform stability studies for your specific formulation.
Dosage Form Considerations:
Oral Suspensions: A common choice for dose titration or pediatric (off-label) use. Ensure uniform dispersion to prevent settling and dose variation.
Capsules: Allow for precise dosing and can be a good option for patients who dislike tablets.
Stability and Beyond-Use Dating (BUD): Without formal stability studies, USP <795> guidelines for non-sterile compounding require a conservative BUD. For water-containing formulations, it’s typically ≤ 14 days when refrigerated. Investing in stability testing can allow you to assign a longer BUD, reducing waste and improving patient convenience.
Patient Counseling: This is paramount. Counsel patients on:
Proper storage (often refrigeration).
Correct administration (e.g., shaking the suspension vigorously for 30 seconds).
The importance of adherence despite the absence of taste-masking in commercial tablets.
Cost-Effective Bulk Purchasing Strategies for Elagolix API Importers
Forecast Demand Accurately: Use market data, prescription trend reports, and internal sales forecasts to predict your API needs. It allows you to negotiate from a position of knowledge and avoid costly last-minute purchases.
Establish Long-Term Agreements (LTAs): Secure your supply chain and lock in favorable pricing by negotiating LTAs with qualified manufacturers. It protects you from short-term fluctuations in market prices.
Consider Consortium Buying: If you are a smaller importer, explore forming a buying consortium with other non-competing companies to achieve volume discounts that would otherwise be unavailable.
Total Cost of Ownership (TCO): Look beyond the price per kilogram. Factor in:
Shipping and insurance costs.
Customs duties and tariffs.
Storage costs (especially for cold-chain items).
Costs of quality testing and validation.
A slightly higher API price from a more reliable supplier may result in a lower TCO by reducing risk, rejected batches, and supply disruptions.
Currency Hedging: If dealing with international suppliers, consider hedging strategies to protect against adverse currency movements.
Elagolix Emerging Applications and Future Outlook
The future of Elagolix is bright, indicating a long-term demand for its API.
Uterine Fibroids: AbbVie has already developed Oriahnn™ (elagolix, estradiol, and norethindrone acetate), a combination product for the treatment of heavy menstrual bleeding associated with uterine fibroids. It validates the API’s utility in this large market.
Adenomyosis: Significant off-label use and ongoing research show promising results.
Oncology: Research is exploring its use in hormone-sensitive cancers, such as prostate and breast cancer.
Pediatric Endometriosis: While currently off-label, there is a growing need for treatment options for adolescents, often met by compounding pharmacies.
Staying informed about Phase II and III clinical trials for these indications will allow your business to anticipate shifts in demand and position itself as a knowledge leader.
Conclusion: Positioning Your Business in the Elagolix Supply Chain
Elagolix is more than just another API; it is a cornerstone of modern endocrine therapy with a growing list of applications.
For API importers, manufacturers, and compounding pharmacies, it represents a significant opportunity for growth, innovation, and immense value to healthcare providers and patients.
Success in this market hinges on an unwavering commitment to sourcing high-quality ingredients, expertise in formulation and compounding, and strategic foresight to navigate the evolving clinical landscape.
By leveraging the detailed information in this guide, you can make data-driven decisions, mitigate supply chain risks, and ultimately become a trusted partner in the Elagolix ecosystem.
The demand for high-quality Elagolix API and innovative formulations is only set to increase.
Now is the time to build your strategy and capture your share of this dynamic market.
Disclaimer:
This content is for informational purposes only and is intended for business-to-business communication within the pharmaceutical industry. It is not intended as medical advice. The manufacture, import, and use of Elagolix API must comply with all applicable laws and regulations in the relevant country or region.
This blog post is informational only and does not constitute medical advice.
Always consult a healthcare professional before starting any new medication or treatment.
